Does tucatinib cross the blood-brain barrier?

Tucatinib is able to cross the blood-brain barrier. Tucatinib (Tucatinib) is an oral drug with the unique ability to cross the blood-brain barrier. This means it can cross the blood-brain barrier and enter the central nervous system, which is particularly important for treating possible brain metastases in patients with HER2-positive breast cancer. Traditional HER2 targeted therapeutic drugs have limited effectiveness in crossing the blood-brain barrier, and this property of tucatinib gives it certain advantages in the treatment of HER2 brain metastases from positive breast cancer.

For HER2 positive breast cancer patients, brain metastasis is a very important and difficult problem. Tucatinib can cross the blood-brain barrier and directly inhibit cancer cells in the brain, thereby significantly reducing the risk of death in breast cancer patients and effectively dealing with brain metastasis. Clinical studies have shown that tucatinib, when used in combination with capecitabine and trastuzumab (Herceptin), can significantly reduce the risk of disease progression or death in patients with HER2-positive breast cancer.

Tucatinib’s ability to cross the blood-brain barrier is supported by multiple clinical trials. For example, in the HER2CLIMB phase 2 trial, tucatinib was combined with capecitabine and trastuzumab to treat patients with HER2-positive breast cancer. The results showed that the drug could reduce the risk of progression-free survival (PFS) and extend the survival of patients with brain metastases. This trial data provides strong evidence that tucatinib can cross the blood-brain barrier and exert a therapeutic effect.

Although tucatinib can cross the blood-brain barrier and exert a therapeutic effect, patients should strictly follow the doctor's instructions when taking it and should not stop taking it or adjust the dose on their own. If any discomfort occurs during treatment, you should communicate with the doctor in time. Female patients of childbearing potential should use effective contraception during treatment.

References:

https://www.lbbc.org/news/tucatinib-plus-t-dm1-effective-against-her2-positive-breast-cancer